Evidence map›Paper›PMID 23299436›Full record

ArticleInternational journal of molecular sciences2013

Detection of tumor cell-specific mRNA in the peripheral blood of patients with breast cancer—evaluation of several markers with real-time reverse transcription-PCR.

Ulrich Andergassen, Simone Hofmann, Alexandra C Kölbl, Christian Schindlbeck, Julia Neugebauer, Stefan Hutter, Verena Engelstädter, Matthias Ilmer, Klaus Friese, Udo Jeschke

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ulrich AndergassenKlinik und Poliklinik für Frauenheilkunde und Geburtshilfe Ludwig-Maximilians-Universitaet Muenchen, Campus Innenstadt, Maistraße 11, 80337 Munich, Germany. udo.jeschke@med.uni-muenchen.de.
Simone Hofmann
Alexandra C Kölbl
Christian Schindlbeck
Julia Neugebauer
Stefan Hutter
Verena Engelstädter
Matthias Ilmer
Klaus Friese
Udo Jeschke

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It is widely known that cells from epithelial tumors, e.g., breast cancer, detach from their primary tissue and enter blood circulation. We show that the presence of circulating tumor cells (CTCs) in samples of patients with primary and metastatic breast cancer can be detected with an array of selected tumor-marker-genes by reverse transcription real-time PCR. The focus of the presented work is on detecting differences in gene expression between healthy individuals and adjuvant and metastatic breast cancer patients, not an accurate quantification of these differences. Therefore, total RNA was isolated from blood samples of healthy donors and patients with primary or metastatic breast cancer after enrichment of mononuclear cells by density gradient centrifugation. After reverse transcription real-time PCR was carried out with a set of marker genes (BCSP, CK8, Her2, MGL, CK18, CK19). B2M and GAPDH were used as reference genes. Blood samples from patients with metastatic disease revealed increased cytokine gene levels in comparison to normal blood samples. Detection of a single gene was not sufficient to detect CTCs by reverse transcription real-time PCR. Markers used here were selected based on a recent study detecting cancer cells on different protein levels. The combination of such a marker array leads to higher and more specific discovery rates, predominantly in metastatic patients. Identification of CTCs by PCR methods may lead to better diagnosis and prognosis and could help to choose an adequate therapy.

Indexed as

Biomarkers, TumorBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesFemalegamma-SynucleinGene Expression Regulation, NeoplasticHumansKeratin-18Keratin-19Keratin-8KeratinsMammaglobin ANeoplasm MetastasisNeoplasm ProteinsNeoplastic Cells, CirculatingPrognosisBiomarkers, TumorErb-b2 Receptor Tyrosine Kinasesgamma-SynucleinKeratin-18Keratin-19Keratin-8KeratinsMammaglobin ANeoplasm ProteinsRNA, MessengerSNCG protein, human

Identifiers

PMID23299436
PMCPMC3565309

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.